Microdosing Ozempic/Wegovy  & Zepbound/Mounjaro for Weight Loss, Maintenance, and Inflammation

A hand with a red area indicating discomfort, labeled 'Microdosing of GLP-1's Reduces Inflammation'. Below, various GLP-1 medications are displayed: Mounjaro, Wegovy, Trulicity (1.5 mg), and Ozempic, suggesting their use in treatment.

GLP-1 microdosing reduces inflammation

by Dr Richard Lipman MD. Endocrinologist,
Reviewed and Rewritten  March 3rd, 2026 

Including Microdosing Tables for GLP-1’s

Microdosing GLP-1 medications, including Ozempic/Wegovy and Zepbound/Mounjaro, for weight loss and maintenance means taking lower than the FDA-approved starting, titration, and maintenance doses while achieving the same metabolic effects. Microdosing offers several advantages, especially for individuals who are new to GLP-1 medications, are sensitive to gastrointestinal side effects like nausea and bloating, and even for groups with medical problems not related to weight loss. These benefits include:

  • Improved tolerability with much fewer side effects — Ideal for patients over 50 or those with a history of sensitivity, usually gastrointestinal. Telemedicine: patients can make rapid changes in their doses. The goal is to minimize side effects, especially gastrointestinal ones (nausea, bloating, constipation), while still gaining s appetite control and weight loss.
  • Cost-effective — Patients paying out-of-pocket can stretch a single pen over multiple weeks
  • Better adherence — A gentler start reduces dropouts.
  • Microdosing GLP-1’s  to treat other unrelated illnesses
  • Microdosing GLP-1’s to treat comorbidities of obesity. Individuals taking these medications are dealing not only with their excess weight but with numerous comorbidities like hypertension, diabetes, heart failure, strokes, sleep apnea, and arthritis. Many of these comorbidities are also reduced with GLP-1 medications, even at the very low doses used in microdosing.

 Microdosing for Weight Loss and Maintenance

1. Microdosing for Weight Loss
Even though GLP-1 doses are much lower than those approved by the FDA,  I have seen both immediate weight reduction and prolonged weight control in hundreds of patients. We have found that microdosing GLP-1 medications yields comparable weight-loss results with reduced costs and side effects, while also improving availability.

2. Microdosing for Weight Maintenance
Typical starting and maintenance doses may be 50% of the usual dosages. Other studies using less than 0.4 mg of semaglutide showed  13-14% weight loss. I have more than 50 patients losing in excess of 50 lbs while taking 0.25 mg of tirzepatide to lose and then maintain their weight; almost all of these have noted improvements in blood pressure, arthritis, and blood lipids despite very low doses. The interesting observation is that this does not take months and months to appear. It can appear after two or three months of treatment.

Microdosing GLP-1’s for other Unrelated Medical Problems: 

        1. Ozempic and Alzheimers Disease
          Several clinical trials are studying semaglutide, the main ingredient in Ozempic, as a possible treatment for Alzheimer’s disease. Results are expected in 2026. Early research suggests semaglutide might lower the risk of developing Alzheimer’s. Some studies show it could slow memory loss and brain shrinkage in people with the disease. GLP-1 medications like semaglutide may protect the brain by improving blood vessel health, reducing inflammation, and affecting metabolic processes linked to Alzheimer’s. However, these findings are early, and more research is needed to confirm if GLP-1 drugs are safe and effective for treating Alzheimer’s.

  1. GLP-1’s in mental health and addiction
    GLP-1 receptor medications affect the brain by reducing appetite and cravings for alcohol. Some people taking Ozempic and Zepbound have noticed mood improvements and feel more emotionally stable, with less anxiety and depression. Researchers are studying GLP’-1’s as a treatment for alcohol abuse and other mental health conditions, and a few small studies have shown positive results.
  2. Ozempic and longevity
    The SELECT trial followed 17,604 people with obesity and heart disease for three years, comparing semaglutide (Ozempic) to a placebo. During the study, 833 participants died, but those who took Ozempic had a lower risk of dying from heart-related and other causes. Strong evidence shows Ozempic helps people with obesity, diabetes, and heart disease. However, whether Ozempic can help otherwise healthy people live longer is still being studied.

 Microdosing of Wegovy and Zepbound: The Starting Dose:

Microdosing GLP-1 medications for weight loss and maintenance typically begins with a starting dose, usually half the usual dose (0.125 mg) or one-quarter of the usual dose (0.0625 mg). These doses are well below the “normal” therapeutic levels. Often, this is done for medical reasons in addition to the other reasons described here. When using very low doses, watch the syringe size; use small syringes, such as 0.3 cc or, at most, 0.5 cc, for accurate measurements.

Microdosing of Wegovy in Individuals with History of GERD

For example, the starting dose of Wegovy is 0.25 mg/week. Individuals with a history of GERD, heartburn, gastritis, or taking Pepcid or other acid blockers are often started on  0.125  mg per week and advanced more slowly. This dose can often be lower and split into two equal doses during the week. They may lose most of their weight on 0.75 to 1 mg per week or less. The patient has fewer side effects, spends less money, and finds the pens easier to find.

Microdosing of Zepbound in Elderly Patients

Another example might be an older patient taking many medications for heart failure and kidney disease. It might be best to start him on half the starting dose of Zepbound, such as 1.25 mg/week, then increase the dose at half the usual intervals.  The strategy behind microdosing GLP-1 receptor agonists involves using lower doses to achieve weight-loss benefits while limiting side effects associated with higher doses. GLP-1 medications trigger weight loss through multiple mechanisms: they promote insulin secretion while reducing glucagon release, delay gastric emptying, and decrease appetite.

Microdosing of Wegovy and Zepbound—Titrating to Higher Doses:

Microdosing GLP-1 medications yields weight-loss results often comparable to those achieved with higher doses. Standard medications such as semaglutide (Wegovy) lead to marked weight loss (15-20% of body weight), but early clinical evidence and anecdotal reports suggest that lower doses can also achieve similar weight loss, though the percentage may be slightly lower. microdosing..

Patients who respond well to low doses but are concerned about potential side effects of higher doses will find this phenomenon advantageous. Microdosing promises sufficient appetite control and metabolic benefits while avoiding the increased risk of gastrointestinal side effects, including nausea and vomiting.

The potential for reduced costs is one of the strongest arguments for using microdosed GLP-1 medications. The full doses of GLP-1 medications prescribed for weight loss treatment tend to have high costs and often limited availability. The monthly cost of Wegovy (Semaglutide) treatment ranges between $1,300 and $1,500.

Microdosing Reduces Costs, Which Encourages Continued Therapy

Financial constraints prevent many patients from accessing weight loss treatments, while microdosing serves as a more affordable solution. Microdosing these medications expands accessibility to weight loss treatments for patients who do not have insurance plans that cover such drugs. Microdosing also makes GLP-1 medications more accessible. Full-dose GLP-1 medications face availability restrictions in numerous regions due to shortages and supply chain challenges. The distribution of medication demand becomes more balanced

Microdosing GLP-1 medications for weight loss and maintenance means taking lower-than-FDA-approved starting, titration, and often maintenance doses. See Table 1 on microdosing:

Table 1 : Microdosing ScheduleA detailed 12-week microdosing schedule for Semaglutide and Tirzepatide, listing dosage amounts and notes on starting low, gradual increases, and optional additional doses for weight loss management.

Microdosing of GLP-1 Permits Active Weight Loss

Those actively working to lose weight can achieve effective results with microdosing. The belief that higher-dose GLP-1 medications produce faster weight loss contrasts with the idea that microdosing can still effectively suppress appetite and aid fat loss over time. The gradual weight loss produced by microdosing offers a more sustainable weight-management option for those who favor slow progress over faster but potentially unsustainable weight loss.

Microdosing of GLP-1’s Encourages Long-Term Weight Maintenance

A primary problem in weight-loss treatment is maintaining weight loss over the long term. Maintaining new body weight presents a significant challenge for many people after they have lost weight. Microdosing GLP-1 medications is a potential long-term weight-maintenance strategy because these medications regulate appetite and sustain metabolic health at minimal doses, at low cost, and with greater availability. Even a single injection a month will maintain weight loss!

Microdosing of GLP-1’s: What are the differences in the Medications

Microdosing can be implemented across all available GLP-1 receptor agonists, but requires consideration of each drug’s unique properties.

Semaglutide (Wegovy/Ozempic) is among the leading GLP-1 medications for weight reduction. This medication requires weekly administration and yields significant weight loss. Microdosing Semaglutide is an attractive option for people who want to lose weight gradually while experiencing fewer side effects.

Tirzepatide (Mounjaro/Zepbound) is a dual agonist medication that targets both GLP-1 and GIP receptors. This positions it as a highly effective treatment for weight loss. Microdosing Tirzepatide currently yields the most significant weight loss.

Microdosing GLP-1 drugs offers a promising weight-loss approach that balances effectiveness with cost-efficiency and manageable side effects, while improving access. Research needs to continue to achieve a complete understanding of the long-term effects, while early evidence indicates that microdosing is effective for weight reduction and long-term maintenance. The introduction of microdosing as an affordable, easily accessible treatment improves the success rates of GLP-1 therapy for obesity and metabolic health management.

Microdosing of Ozempic Differs from Other GLP-1’s

When it comes to Ozempic, microdosing differs from the other three medications because of the Ozempic pen’s design. Older than the other pens currently used for Zepbound, Mounjaro, and Wegovy, this pen allows multiple doses by “clicking” a wheel at the end. By counting clicks, very small doses of Ozempic can be administered:

Microdosing Differences Between GLP-1 Medicationsmicrodosing of Ozempic by counting clicks

Microdosing can be implemented across all currently available GLP-1 receptor agonists, but it requires consideration of each drug’s unique properties.

* Semaglutide (Wegovy/Ozempic) stands out as one of the leading GLP-1 medications used for weight reduction. This medication requires weekly administration and yields significant weight loss. Microdosing Semaglutide stands out as an attractive option for people who want to lose weight gradually while experiencing fewer side effects.

* As a dual agonist medication, Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors, which positions it as a highly effective treatment for weight loss. Microdosing tirzepatide has not been extensively researched yet shows promise as a superior treatment for appetite reduction and fat burning through lower doses.

* The medication Liraglutide (Saxenda) serves as a GLP-1 agonist to aid weight loss, although it needs daily injections. Microdosing Liraglutide offers a more practical treatment option for patients who require lower doses and less frequent medication administration.

Ideal candidates for Microdosing:

  • Over 50 or with a slower metabolism
  • History of GI side effects on GLP-1s or history of gastric disease as evidenced by taking prescription medications
  • Paying out of pocket (can stretch a pen over 8–10 weeks)
  • Restarting after stopping due to intolerance

Microdosing involves Special Considerations:

  • Requires medical supervision: Microdosing is off-label and not supported by the drug’s labeling. Patients must be trained in sterile technique and in precise dosing.
  • Pens are not designed for this use: You must bypass the pen’s click-delivery system and either use vials from Lilly Direct or manually remove the medication from the vials. We suggest small  0.5cc insulin or even 0.3cc insulin syringes for the injection
  • No official support from Eli Lilly, but widely used by physicians in private weight-loss practices and telemedicine. One of the most cost-saving benefits is learning to extract the GLP-1 from 15 mg pens. There are several techniques for this, and an easy way to find them is to search YouTube videos.

Microdosing of GLP-1 Medications Offers Many Advantages to GLP-1 Successful Weightloss

Microdosing GLP-1 drugs presents a promising weight-loss approach by offering a balance of effectiveness, cost-efficiency, and manageable side effects, with better access. 

At Dr. Lipman’s Miami Diet Plan, we offer personalized care to patients seeking weight management and glycemic control with semaglutide and tirzepatide. This includes Qsymia, Wegovy, Zepbound, and Mounjaro. We offer microdosing of these medications, starting with the lowest doses, biweekly or even triweekly dosing, and once-monthly maintenance treatments. Our microdosing is always individualized for each patient, with the goals of maximizing weight loss and minimizing side effects at the lowest possible dose. Our team provides:

    • Expert guidance on dosing strategies.
    • Tailored treatment plans, including microdosing options.
    • Comprehensive support for long-term success.

Contact us today to schedule a consultation and start your journey to better health with Semaglutide and Tirzepatide Medications

The introduction of microdosing as both an affordable and easy-to-access treatment improves GLP-1 therapy success rates for obesity and it’s metabolic complications. New studies are finding multiple benefits of microdosing, including reduced inflammation in many organs, especially muscles and joints. Let us help you achieve lasting results and improved well-being!